Monsanto Yields

So Monsanto’s seeds and trait sales and earnings won’t grow to the sky forever. Monsanto has had an impressive run since its 2000 spin off from Pharmacia, with profits and its market capitalization up more than fivefold. The mid-2008 commodity and financial bust pushed the stock off its peak, but a fierce customer push back on pricing now has the company ratcheting down earnings expectations. Monsanto dominated the battle over first-generation biotech seeds and traits—those largely focused on input traits such as...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers